产品
编 号:F757708
分子式:C14H7N9O3
分子量:349.26
产品类型
结构图
CAS No: 354543-09-2
联系客服
产品详情
生物活性:
LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC50s of 2.99 and 2.47 μM, respectively.
体内研究:
LQZ-7F (i.p. injection; 25 mg/kg once every 3 days; 24 days) inhibits growth of xenograft tumor and may be due to its induction of surviving degradation in vivo.Animal Model:4- to 6-week-old male NSG (NOD/SCID/IL-2Rg null) mice.
Dosage:25 mg/kg
Administration:24 days
Result:Inhibited growth of xenograft tumors by inhibiting surviving.
体外研究:
LQZ-7F could be hudrolyzed under acidic conditions.LQZ-7F (2.5 μM, 72 hours) displays cytotoxicity towards human cancer cells (PC-3, C4-2) with the IC50s of 2.99 μM and 2.74 μM, respectively.LQZ-7F effectively inhibits survival of all cancer cell lines with IC50 values ranging between 0.4 and 4.4 mM.LQZ-7F (2 μM, 24 hours) disrupts microtubule structure and cause mitotic arrest in P3 cells.